For the second time in two days, Anglo-Swedish pharma company AstraZeneca (LSE: AZN) announced that the US Food and Drug Administration (FDA) had given Breakthrough Therapy designation to one of its oncology medicines.
In fact, acalabrutinib is the fifth AstraZeneca cancer drug to be given this status since 2014, albeit the first for the company in hematology.
"Acalabrutinib is a potent, irreversible BTK inhibitor with a high degree of specificity for its target"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze